Prevalence of peanut sensitization in a population of 4,137 patients referred to allergologists: An Allergo-Vigilance Network enquiry carried out in 2002

Morisset M¹, Moneret-Vautrin DA¹, Kanny G¹, Rance F², Bosse I³, Buard M⁴, Gallen C⁵.

¹Department of Internal Medicine, Clinical Immunology and Allergology University Hospital - 29 avenue du Maréchal de Lattre de Tassigny – 54035 NANCY Cedex
²Department of Pediatrics University Hospital 330 av de Grande Bretagne – 33026 TOULOUSE Cedex
³27 rue Villeneuve – 17000 LA ROCHELLE
⁴5 rue Marteille – 35000 RENNES
⁵Allergology Unit Hospital – Bld Dr Lacroix - 11100 NARBONNE

Abstract

A total of 4,137 people consulting allergologists were routinely tested for peanut sensitization. The study involved 86 allergologists in the Allergo-Vigilance Network over a period of 30-60 consecutive days. Investigation procedures were identical. Results classified subjects into four groups: Group 1: subjects suspected of having a food allergy; group 2: subjects with ongoing atopic disease; group 3: subjects with an underlying predisposition to atopy, as showed by one or more positive results to prick-tests with airborne allergens; group 4: non atopic subjects. The sensitization rates were 22.7%, 8.7%, 4%, and 0.4% respectively. Assuming that 25% of the French population is allergic, the rate of sensitization to peanut in the general population should be between 1% and 2.5%. Considering a ratio of 3.3 between sensitization and clinical allergy as plausible, the prevalence of peanut allergy could be 0.3% to 0.75% of the French population. This figure is lower than that for the UK, the US and Canada (0.8% to 1.5%). The correlation between the data in this study and those from previous epidemiological studies validates the methodology used in this type of enquiry.

Key-words: peanut, sensitisation, prevalence, risk factors.
One of the aims of the Allergo-Vigilance Network set up in 2001 is to collect data from a large number of people (1, 2). We present here the results of a study carried out in 2002 by 86 allergologists in the Allergo-Vigilance Network. The primary aim was to assess the prevalence of peanut sensitization in the French population seeking treatment for various allergic disorders. The second objective was to determine whether there was any difference in risk of peanut sensitization in people with ongoing atopic disease, in those with an underlying predisposition to atopy (shown by positive prick-tests) and finally in non atopic people.

**Methodology**

For one month, prick-tests to peanut were carried out systematically on all patients whose disorder justified undergoing prick-tests. To avoid bias, only patients seen for the first time were included.

For the prick-tests, either native peanut (powdered grilled peanut) or an allergen extract (Allerbio or Stallergènes) was used. The criteria for positive prick-tests were defined as follows:
The negative control (to saline) being definitively negative:
- If the histamine or codeine control was $\geq 3$ mm, the prick- test to peanut was positive if $\geq 3$ mm.
- If the positive control was $\leq 3$ mm, the prick-test to peanut was positive if showing the same size as the positive control.

The patients were classified into four groups:

**Group 1**
Those suspected of having food allergy based on clinical features and time elapsing between ingestion of food and symptoms.

**Group 2**
Those being treated for atopic disease (atopic dermatitis, allergic rhinitis, allergic asthma) and for whom allergy tests confirmed sensitization to at least one common airborne allergen.

**Group 3**
Those seen for diverse reasons but for whom the prick-tests with the 12 reference airborne allergens evidenced sensitization to at least one airborne allergen (underlying atopic predisposition).
**Group 4**  
Non atopic people seen for various reasons: for example, reaction to medicinal products or vague skin reactions, but without a history of atopy and negative to prick-tests with common airborne allergens.

**Results:**

86 allergologists responded, of whom 73 were in France and 4 were in French overseas territories (Fort de France: 1, Pointe-à-Pitre: 2, Reunion island: 1). Seven were in foreign countries (Algeria: 1, Belgium: 3, Morocco: 1, Poland: 1, Switzerland: 1).

In France, the replies were distributed as follows:

- North: 51
- South: 22

Precise data about the nature of the extract used for prick-tests were obtained from the French allergologists: an extract from Stallergènes: 40 allergologists, an extract from Allerbio: 27 allergologists, native grilled peanut: 5 allergologists. Twelve ones did not specify the extract used.

A total of 4,137 people underwent prick-tests to peanut. Since there was no significant difference in results depending on the allergen extracts used, the analysis was performed on pooled skin prick-tests.

**Prevalence of peanut sensitization according to group and location**

**Group 1: 946 people**  
A high rate of peanut sensitization was detected in those with suspected food allergy. It was significantly higher in France than in the overseas territories (p < 0.001). There was a significant difference (p< 0.05) between prevalence in the South of France (25.3%) and the North of France (21.4%).

**Group 2: 2,609 people with ongoing atopic disease (Table 2)**  
The results for the South and North of France were similar: 8.8% and 8.5%. There was a significant difference (p < 0.001) in the combined prevalence in foreign countries and French overseas territories compared to that for France.

**Group 3: 298 people with underlying atopic predisposition**  
The rate of underlying sensitization was between 3% and 6.7% (p > 0.1). There was no difference in prevalence between foreign countries and French overseas territories.
**Group 4: 884 people (Table 4)**
The prevalence of peanut sensitization was low: 0.4%, slightly higher in French overseas territories (p < 0.05). Comparative figures for countries are given in Table 5.

**Discussion**

When people with a definite predisposition to atopy, meeting specific criteria, are considered (groups 2 and 3: 2,907 subjects) together with the non atopic group (group 4: 884 subjects), it seems that the atopic population represents at least 76.7% of the total population referred to allergologists, instead of 25% in the global population.

Inter-country comparisons must be interpreted with care. In order to avoid comparisons based on different diagnostic approaches for food allergy, only group 2 (subjects with ongoing atopic disease) will be taken into account. In this group, peanut sensitization appears to be less frequent in Martinique, Guadeloupe, Algeria and Morocco than in France.

One study has demonstrated a peanut sensitization rate of 6.8% in a group of adults positive to one or more RAST tests (6). It must be noted that this group consisted of atopic people similar to those in groups 2 and 3 of this study, where the figures for sensitization were respectively 8.6% and 4% (Table 5). The mean of these estimates is therefore consistent with the referenced study.

Taking the complete sample of groups 2, 3, 4 (3,791), with 352 subjects sensitized to peanut, the peanut sensitization rate is 9.28%.

If an estimated 25% of the entire French population (60 million people) have a predisposition to atopy (i.e. 15 million), the rates of peanut sensitization observed (3% to 8.8%, i.e., the minimal and maximal figures in groups 2 and 3) plausibly represent from 450,000 to 1,320,000 people. An extra 0.4% can be added for potential non atopic people with peanut sensitization; that is a further 180,000. Overall, the rate of peanut sensitization could be between 1.05% and 2.5%. This value is comparable to those for children in other countries: 1.5% to 3.3% in the United Kingdom (3, 4).

Is it possible to assess the possible prevalence of peanut allergy in France from the estimated prevalence of sensitization? This is to question the relationship between sensitization and clinical allergy. Only one study, in children, suggests a 3.3 ratio between sensitization and allergy. If we hypothesize that this is true for adults, peanut allergy could affect 190,000 to 454,000 people, indicating a prevalence of 0.3% to 0.75%. It is currently estimated at 0.8% in the US (7), 1% in the UK (4) and 1.5% in Canada (5).
Our estimates, made by 86 allergologists who followed identical procedures over the same period, are very similar to those found in the literature. This argues in favour of using this methodology to carry out allergological enquiries, as well as the standard epidemiological studies that are much more complicated to implement and last much longer.

A future objective of the Allergo-Vigilance Network could be to monitor the progress of what is often a very severe food allergy by a more specific enquiry into the exact ratio between sensitization and allergy to peanut in a test population.

We thank L Parisot, clinical research assistant for its contribution

References:


7. Sicherer SH, Munoz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random

Table 1
Prevalence of peanut sensitization in 946 people with suspected food allergy

<table>
<thead>
<tr>
<th></th>
<th>Positive prick-tests (PT) (n)</th>
<th>Negative prick-tests (PT) (n)</th>
<th>% positive PT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign countries and French overseas territories</td>
<td>14</td>
<td>178</td>
<td>7.3 %</td>
</tr>
<tr>
<td>France (South)</td>
<td>61</td>
<td>180</td>
<td>25.3 %</td>
</tr>
<tr>
<td>France (North)</td>
<td>110</td>
<td>403</td>
<td>21.4 %</td>
</tr>
</tbody>
</table>

Table 2
Prevalence of peanut sensitization in 2,609 people with ongoing atopic disease

<table>
<thead>
<tr>
<th></th>
<th>Positive prick-tests (PT) (n)</th>
<th>Negative prick-tests (PT) (n)</th>
<th>% positive PT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign countries and French overseas territories</td>
<td>32</td>
<td>630</td>
<td>4.83 %</td>
</tr>
<tr>
<td>France (South)</td>
<td>71</td>
<td>735</td>
<td>8.8 %</td>
</tr>
<tr>
<td>France (Nord)</td>
<td>97</td>
<td>1044</td>
<td>8.5 %</td>
</tr>
</tbody>
</table>

Table 3
Prevalence of peanut sensitization in 298 people without ongoing atopic disease, but with a predisposition to atopy as determined by prick-tests to airborne allergens

<table>
<thead>
<tr>
<th></th>
<th>Positive prick-tests (PT) (n)</th>
<th>Negative prick-tests (PT) (n)</th>
<th>% positive PT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign countries and French overseas territories</td>
<td>3</td>
<td>42</td>
<td>6.7 %</td>
</tr>
<tr>
<td>France (South)</td>
<td>5</td>
<td>82</td>
<td>5.7 %</td>
</tr>
<tr>
<td>France (Nord)</td>
<td>5</td>
<td>161</td>
<td>3 %</td>
</tr>
</tbody>
</table>
# Table 4
Prevalence of peanut sensitization in 884 non atopic people

<table>
<thead>
<tr>
<th></th>
<th>Positive prick-tests (PT) (n)</th>
<th>Negative prick-tests (PT) (n)</th>
<th>% positive PT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign countries and French overseas territories</td>
<td>2</td>
<td>125</td>
<td>1.6 %</td>
</tr>
<tr>
<td>France (South)</td>
<td>1</td>
<td>246</td>
<td>0.4 %</td>
</tr>
<tr>
<td>France (Nord)</td>
<td>2</td>
<td>508</td>
<td>0.4 %</td>
</tr>
</tbody>
</table>

# Table 5
The prevalence of peanut sensitization by country

<table>
<thead>
<tr>
<th></th>
<th>France</th>
<th>Belgium and Switzerland</th>
<th>Poland</th>
<th>Algeria and Morocco</th>
<th>West Indies and Reunion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of subjects investigated</td>
<td>3711</td>
<td>238</td>
<td>122</td>
<td>351</td>
<td>315</td>
</tr>
<tr>
<td>I % positive PT</td>
<td>22.7 %</td>
<td>14.3%</td>
<td>6.1 %</td>
<td>21.6%</td>
<td>2.8%</td>
</tr>
<tr>
<td></td>
<td>171/754</td>
<td>5/35</td>
<td>5/82</td>
<td>8/37</td>
<td>1/36</td>
</tr>
<tr>
<td>II % positive PT</td>
<td>8.6%</td>
<td>16.5%</td>
<td>11.5%</td>
<td>1.3%</td>
<td>3.8%</td>
</tr>
<tr>
<td></td>
<td>168/1947</td>
<td>17/103</td>
<td>3/26</td>
<td>4/310</td>
<td>8/208</td>
</tr>
<tr>
<td>III % positive PT</td>
<td>4 %</td>
<td>2.8%</td>
<td>Ne</td>
<td>Ne</td>
<td>2.9%</td>
</tr>
<tr>
<td></td>
<td>10/253</td>
<td>1/36</td>
<td>1/8</td>
<td>1/1</td>
<td>1/34</td>
</tr>
<tr>
<td>IV % positive PT</td>
<td>0.4%</td>
<td>1.2%</td>
<td>Ne</td>
<td>Ne</td>
<td>2.9%</td>
</tr>
<tr>
<td></td>
<td>3/757</td>
<td>1/82</td>
<td>0/5</td>
<td>0/3</td>
<td>1/35</td>
</tr>
</tbody>
</table>

Statistical analysis was not carried out on the results for groups with < 26 prick-tests.